| Name | Title | Contact Details |
|---|
The PCI Security Standards Council is a global open body formed to develop, enhance, disseminate and assist with the understanding of security standards for payment account security. The Council maintains, evolves, and promotes the Payment Card Industry Security Standards. It also provides critical tools needed for implementation of the standards such as assessment and scanning qualifications, self-assessment questionnaires, training and education, and product certification programs.
The University at Albanys East Campus, featuring the co-location of university research faculty, academic programs and private research-driven companies not only on the same campus but actually in the same buildings, epitomizes what can be accomplished through true partnerships. In less than five years since its creation, the 58-acre East Campus has expanded in research, educational programs and economic outreach at the pace of the burgeoning science of biotechnology that inspired.
Consilium Consulting Inc is a Hanover Park, IL-based company in the Business Services sector.
Shumsky Enterprises is a Dayton, OH-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.